Skip to content

Person-checked company records fromPerson-checked records $750See a worked exampleHuman review in progress

Talk to sales

KeptIndex

Moderna

Report data from the Phase 3 seasonal flu and COVID-19 combination vaccine study (mRNA-1083)

Delivered by the deadline

AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.

Announced
8 Jan 2024
Due
31 Dec 2024
  • Deadline
  • Met
  • Late
  • Not met
  • Today

What the company said

“The Company anticipates data from the study in 2024.”
  • SourceModerna Form 8-K press release, 2024-01-08
  • FilingSEC filing index
  • Deadline as statedin 2024
  • Deadline used31 Dec 2024, the last day of the stated period
  • TypeProduct
  • Permanent referenceKI-C-2024-MRNA-006210
    Cite as https://keptindex.org/c/KI-C-2024-MRNA-006210/ — this address never changes.

What we found

Evidence strength A What the grades mean

Moderna shared positive Phase 3 immunogenicity data for mRNA-1083 at its 2024 R&D Day event, within the 2024 timeframe. Later filings describe the BLA withdrawal, which is a separate regulatory matter.

  • A
    Moderna 10-K filed 2025-02-21 Regulatory filing · published 21 Feb 2025 · retrieved 10 Oct 2026 · kept permanently by the SEC · fingerprint e2b7c6073e1a
    “We shared positive Phase 3 immunogenicity data for our flu+COVID combination vaccine (mRNA-1083) for adults aged 50 years and older at our 2024 R&D Day event.” ✓ confirmed on the page
  • A
    Moderna 10-Q filed 2025-08-01 Regulatory filing · published 1 Aug 2025 · retrieved 10 Oct 2026 · kept permanently by the SEC · fingerprint 7a4f5e9e64f8
    “In May 2025, we announced that in consultation with the FDA, we had voluntarily withdrawn the pending Biologics License Application (BLA) for mRNA-1083” ✓ confirmed on the page

Market reaction: the shares moved +1.3% against the S&P 500 over the three sessions around the disclosure (20 Feb 2025 to 25 Feb 2025). What this measures

Checked 10 Oct 2026.

Commitment DNA

The structured record of this commitment. Fields the company did not state are left blank rather than guessed.

Event type
Clinical readout late
Indicative materiality
High rules
Action
Report
Deliverable
Phase 3 data for mRNA-1083 flu and COVID-19 combination vaccine
Language
Expected (“expects”, “plans”)
In the company’s control
Medium
Specificity
Medium

How this entry was checked

  1. Commitment recordedThe company's words were matched word for word against the filing.
  2. First checkAn AI model, Claude (Anthropic), read the company's later filings and recorded the outcome with a quoted passage.
  3. Second check: agreesA different AI model, Gemini (Google), re-read the evidence without being told the outcome and reached the same answer.

Confirmed. This outcome counts towards the company's Kept Score. How verification works

Are you Moderna? You can publish an official statement next to this entry, free. Add a statement.

Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.

Report an error in this entry Reference: KI-C-2024-MRNA-006210 · Corrections policy

The Deadline Report

One email a week: the corporate commitments that came due, which were met, which slipped, and what is due next. Free. Stop any time.

No advertising. We never sell or share your address.